How a former Pepsi exec leveraged old marketing tactics to build an alcohol startup that's approaching $15 million in revenue this year as pre-mixed cocktails rise in popularity

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. Kevin Folk, Neetu Godara, and Dan Beach, cofounders of Social Lite. Neetu GodaraNeetu Godara, Dan Beach, and Kevin Folk are the cofounders of Social Lite, a line of pre-mixed vodka-soda cocktails with no sugars and artificial ingredients that's set to make $15 million in revenue this year.  Investing $100,000 of their life savings into building the business, Godara, Beach, and Folk got their big break when Liquor Depot, a primary operator in Alberta and British Columbia, shelved their product in 200 stores. Now, Social Lite is available at over 3,000 points of distribution across the US and Canada. Godara credited their success to endless hours of sampling at festivals and stores and selling their product to every stakeholder online and in person.  Hard seltzers and vodka sodas are among the fastest-growing drink segments, particularly now as alcohol sales have spiked during the pandemic. Godara's currently partnering with local influencers to build awareness and expanding her sales team.  Visit Business Insider's homepage for more stories. In the spring of 2014, Neetu Godara met Dan Beach and Kevin Folk, and the three bonded over their mutual love of vodka sodas and discussed how there was nothing on the market, in a To keep reading about How a former Pepsi exec leveraged old marketing tactics to build an alcohol startup that's approaching $15 million in revenue this year as pre-mixed cocktails rise in popularity, Click on the link. Seoul, Korea
http://dlvr.it/Rm5cSb

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Coronavirus Hasn't Diminished Tech Stocks' Allure

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint